Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.
Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. Patick AK, et al. Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50. doi: 10.1128/AAC.43.10.2444. Antimicrob Agents Chemother. 1999. PMID: 10508022 Free PMC article.
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.
Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST. Dragovich PS, et al. Among authors: patick ak. Bioorg Med Chem Lett. 2002 Mar 11;12(5):733-8. doi: 10.1016/s0960-894x(02)00008-2. Bioorg Med Chem Lett. 2002. PMID: 11858991
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.
Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW 3rd, Ferre RA, Worland ST. Dragovich PS, et al. Among authors: patick ak. J Med Chem. 2002 Apr 11;45(8):1607-23. doi: 10.1021/jm010469k. J Med Chem. 2002. PMID: 11931615
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.
Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW 3rd, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS. Johnson TO, et al. Among authors: patick ak. J Med Chem. 2002 May 9;45(10):2016-23. doi: 10.1021/jm010435c. J Med Chem. 2002. PMID: 11985469
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW 3rd, Ferre RA. Dragovich PS, et al. Among authors: patick ak. J Med Chem. 2003 Oct 9;46(21):4572-85. doi: 10.1021/jm030166l. J Med Chem. 2003. PMID: 14521419
In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.
Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ. Patick AK, et al. Antimicrob Agents Chemother. 2005 Jun;49(6):2267-75. doi: 10.1128/AAC.49.6.2267-2275.2005. Antimicrob Agents Chemother. 2005. PMID: 15917520 Free PMC article. Clinical Trial.
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.
Webber SE, Okano K, Little TL, Reich SH, Xin Y, Fuhrman SA, Matthews DA, Love RA, Hendrickson TF, Patick AK, Meador JW 3rd, Ferre RA, Brown EL, Ford CE, Binford SL, Worland ST. Webber SE, et al. Among authors: patick ak. J Med Chem. 1998 Jul 16;41(15):2786-805. doi: 10.1021/jm980071x. J Med Chem. 1998. PMID: 9667969
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST. Dragovich PS, et al. Among authors: patick ak. J Med Chem. 1998 Jul 16;41(15):2806-18. doi: 10.1021/jm980068d. J Med Chem. 1998. PMID: 9667970
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST. Dragovich PS, et al. Among authors: patick ak. J Med Chem. 1998 Jul 16;41(15):2819-34. doi: 10.1021/jm9800696. J Med Chem. 1998. PMID: 9667971
74 results